Abstract. The aim of this study was to investigate the effect of cilostazol, a cAMP phosphodiesterase inhibitor, on carotid artery intima-media thickness (IMT) and on the incidence of cardiovascular events in Japanese subjects with type 2 diabetes. A total of 62 type 2 diabetic subjects were allocated equally to the cilostazol treatment group (n = 31) and the control group (n = 31). Carotid IMT was evaluated before and after treatment using B-mode ultrasonography. After the study period (mean ± SD: 2.6 ± 0.17 years), carotid IMT showed a significantly greater increase in the control group than in the cilostazol group (0.12 ± 0.14 mm vs. 0.04 ± 0.02 mm, p<0.05). In the control group, 1 out of 31 patients suffered from symptomatic cerebral infarction and 1 had angina pectoris during the observation period. On the other hand, no subject in the cilostazol group developed cardiovascular events during the study period. At baseline, the diabetic patients given cilostazol had a significantly lower HbA 1c level than the control subjects, but the other atherosclerotic risk factors (BMI, blood pressure, and serum lipids) and the duration of diabetes did not differ between the two groups. These results indicate that cilostazol therapy can attenuate the increase of carotid artery IMT in Japanese subjects with type 2 diabetes.
ULTRASONOGRAPHIC measurement of carotid artery intima-media thickness (IMT) allows noninvasive early detection of atherosclerotic changes [1, 2] and is used as an intermediate marker for assessing the progression or regression of atherosclerosis in clinical trials [3] . Previous large-scale prospective studies of atherosclerosis have shown that baseline carotid IMT is significantly associated with the incidence of stroke or myocardial infarction during follow-up for 7-10 years [4, 5] . Thus, IMT is thought to be a useful predictor of future events due to atherosclerosis. It is known that the onset and the progression of atherosclerosis is much more rapid in diabetic patients than in non-diabetic subjects, and one of the major causes of death in diabetics is atherosclerosis-associated diseases. Therefore, it is important to prevent the development and progression of atherosclerosis in diabetics to improve their prognosis.
The antithrombotic drug, cilostazol, is a type 3 phosphodiesterase inhibitor that has beneficial effects such as increasing peripheral blood flow and inhibiting the proliferation of vascular smooth muscle cells [6, 7] . To clarify the preventive effect of cilostazol on atherosclerosis in diabetics, we performed a randomized trial in patients with type 2 diabetes by evaluating carotid IMT and the incidence of atherosclerotic events over an average period of 2.6 years.
Materials and Methods

Subjects
A total of 62 subjects with type 2 diabetes (aged 50-76 years at enrollment, mean ± SD: 63 ± 7.6 years) were recruited from the outpatients of Juntendo University Hospital. The diagnosis of type 2 diabetes was based on the current criteria of the WHO recommendation [8] . Subjects with ketoacidosis, overt proteinuria, or proliferative diabetic retinopathy were excluded from the study. The subjects were randomly divided into two equal groups to match age and gender with or without cilostazol therapy. The subjects in the cilostazol group (n = 31) received cilostazol at a dose of 100-150 mg/day, while those in the control group (n = 31) did not receive any antithrombotic drugs. All of the patients gave their written informed consent before enrollment in the study, which was approved by the Ethics Committee of Juntendo University.
The characteristics of the subjects are shown in Table  1 . At enrollment, baseline laboratory data, blood pressure, BMI, resting 12-lead electrocardiogram (ECG), and IMT were determined for each patient. Fasting blood samples were obtained for the measurement of serum lipids (total cholesterol, HDL-cholesterol, and triglycerides), serum uric acid, serum creatinine, blood urea nitrogen, and stable glycohemoglobin (HbA 1c ) by standard laboratory techniques. During the mean observation period of 2.6 ± 0.13 years, the lipid profile, plasma glucose and HbA 1c , blood pressure, and BMI were determined every 1-2 months, while IMT was determined annually.
Blood pressure was measured with a standard mercury sphygmomanometer placed on the arm after the subject had been seated for at least 5 min. Hypertension was defined as a systolic blood pressure above 150 mmHg and/or diastolic blood pressure above 90 mmHg and/or use of antihypertensive medication. Hyperlipidemia was considered to be present when the patient had a serum total cholesterol level >220 mg/dl and/or triglyceride level >150 mg/dl and/or was on lipid-lowering medications. Hyperuricaemia was considered to be present when the patient had a serum uric acid level >6.0 mg/dl and/or was receiving uricosuric therapy.
Eleven patients were controlled with diet only, 41 were on oral hypoglycemic agents, and 15 were receiving insulin. Thirty-seven patients had hypertension or were taking antihypertensive drugs (diuretics, b-blockers, a 1 -blockers, Ca-channel blockers, and angiotensin-converting enzyme inhibitors). Antihypertensive drugs were being given to 28 diabetics. Thirty-five patients had dyslipidemia or were on lipidlowering drugs (clofibrate, probucol, and statins). Antihyperlipidemic drugs were being given to 20 diabetics. The dosages of these medications were not altered during the follow-up period.
Assessment of carotid IMT
Ultrasonographic scanning of the carotid arteries was performed using an echotomographic system (EUB-555; Hitachi Medico, Tokyo) with a linear transducer (midfrequency range of 7.5-10 MHz). Scanning of the extracranial carotid arteries in the neck was performed bilaterally in three different longitudinal projections (i.e., anterior-oblique, lateral, and posterior-oblique) and in the transverse projection as previously reported [1, 2, 9] . This method allowed the common carotid artery, the carotid bulb, and the internal carotid arteries to be scanned. All of the images were photographed. Carotid IMT was defined as the distance from the leading edge of the first echogenic line to the leading edge of the second echogenic line on the scans, with the first line representing the lumen-intimal interface and the second line representing the collagen-containing upper layer of the tunica adventitia. Plaque was defined as an area of localized thickening ³1.4 mm. In each longitudinal projection, the site of the greatest IMT thickness (including plaque) was detected by scanning along the vessel from the common carotid artery to the internal carotid artery. Three measurements of the IMT were made, i.e. at the site of greatest thickness and at two other points (1 cm proximal and 1 cm distal to this site), and the 3 values were averaged. The highest value of the 6 averaged IMT values (3 from the left side and 3 from the right side) was used as the representative IMT value) for each patient. The scanning period averaged 30 min and scanning was always performed by a physician. The reproducibility of the IMT measurement was examined by repeating the procedure after 2 weeks in 8 subjects with IMT values of 0.74 to 1.36 mm. The mean absolute difference between the 2 measurements was 0.05 mm and the standard deviation was 0.07 mm, demonstrating good reproducibility.
Statistical analysis
Data are presented as the mean ± SD. Laboratory values were compared by paired t-test and one-way ANOVA. Student's t-test was used for comparing the mean values of variables between diabetic patients with and without cilostazol therapy, whereas the c 2 -test was used for comparing proportions. Stepwise multivariate regression analysis was performed to clarify the factors related to the annual increase of IMT in all subjects. Statistical significance was defined at P<0.05.
Results
The baseline clinical characteristics of the two groups are displayed in Table 1 . Although the baseline HbA 1c was significantly higher in the control group than in the cilostazol group, the other clinical characteristics and carotid IMT showed no significant differences between the two groups.
As shown in Table 2 , the final IMT of the cilostazol group was smaller than that of the control group, but not significantly so (1.12 ± 0.29 vs. 1.20 ± 0.33 mm, p = 0.37). The control group showed a significant increase of IMT during the observation period (increase of 0.12 ± 0.03 mm), while the cilostazol group showed no significant increase during the same period (increase of 0.04 ± 0.02 mm). Since glycemic control may have an effect on IMT increase and HbA1c level at baseline in the control group was significantly higher than in the cilostazol group but not different after treatment, the annual increase rate of IMT was calculated by adjusting mean HbA1c values during the study period. As shown in Figure 1 , adjusted annual increase rate of IMT in the cilostazol group was significantly lower than that in the control group (0.011 ± 0.01 vs. 0.046 ± 0.01 mm/year, p = 0.016).
While one subject suffered from cerebral infarction (CI) and one subject had angina pectoris (AP) in the control group during the observation period, none of the subjects in the cilostazol group had cardiovascular events. However, the difference between the two groups was not significant.
Stepwise multivariate regression analysis was performed to evaluate factors related to the annual increase of IMT. As shown in Table 3 , the baseline triglyceride level was positively correlated and cilostazol treatment was negatively correlated with the annual progression of IMT. According to multiple regression analysis, the baseline HbA 1c level was significantly associated with the initial IMT value (data not shown).
Discussion
The increase of carotid IMT reflects early atherosclerotic changes, whereas stroke, coronary artery disease, and peripheral vascular disease are advanced stages of atherosclerosis. The antiplatelet agent cilostazol has been mainly used for secondary prevention of cardiovascular events related to advanced atherosclerosis or for control of symptoms in the patients with intermittent claudication or skin ulcers [10] [11] [12] . However, the present study showed that cilostazol could attenuate the increase of carotid IMT in type 2 diabetics, and these results were consistent with recent reports about the preventive effect of cilostazol on early atherosclerosis in diabetics [13, 14] . Yamasaki et al. evaluated the effect of cilostazol for average 3.2 years on Japanese type 2 diabetic patients. Although the maximal dose of cilostazol was higher (200 mg daily) and the duration of diabetes in the patients was slightly longer than the present study, the attenuating effect of cilostazol on IMT increase was similar [13] . Ahn et al. evaluated effect of cilostazol in Korean type 2 diabetic patients showing lower levels of baseline IMT than the present study (average 0.94 mm in the left and 0.87 mm in the right common carotid artery), and they observed significant decrease in IMT after 1 year of cilostazol treatment [14] .
Diabetic patients have a two-to four-fold higher risk of dying from cardiovascular complications. Since the major risk factors of atherosclerosis in diabetics are hyperglycemia and insulin resistance, life style modification and optimal drug intervention are important. Recently, even mild type 2 diabetes with normal level of fasting plasma glucose but showing postprandial hyperglycemia is thought to be a significant risk factor for atherosclerosis [15] . We previously reported the effect of nateglinide, a rapid insulin secretagogue, on post prandial hyperglycemia in the subjects with mild type 2 diabetes and impaired glucose tolerance (IGT) [16] [17] [18] . A world wide large scale prospective study of nateglinide for prevention of atherosclerotic events in IGT subjects is now in progress (Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research: NAVIGATOR Study), thus, the importance of ameliorating postprandial hyperglycemia may be clarified near future. One of other significant risk factors for atherosclerotic events in diabetics is a thrombotic tendency. Many previous studies have revealed that platelets from patients with diabetes are hypersensitive to platelet-aggregating agents in vitro and show increased thromboxane production [19, 20] . Although the exact mechanism of platelet hyperactivity is still unclear, an association between enhancement of arachidonic acid metabolism (producing thromboxane) and hyperglycemia-induced oxidative stress has been suggested [20] . Low-dose aspirin blocks thromboxane synthesis by acetylation of platelet cyclooxygenase, and so aspirin is probably the most widely used preventive agent for cardiovascular events. In fact, the American Diabetes Association (ADA) and the U.S. Preventive Services Task Force recommend low-dose aspirin therapy for both non-diabetic and diabetic individuals with cardiovascular risks [21, 22] . However, there are few reports about the effect of aspirin or comparisons between aspirin and cilostazol with respect to early atherosclerotic changes like the increase of carotid IMT [23] . A recent large-scale prospective study evaluating the primary preventive effect of low-dose aspirin on cardiovascular events for a median of 3.7 years (The Primary Prevention Project (PPP) Trial) showed no significant reduction of cardiovascular events or deaths in diabetics, while there was a significant reduction in non-diabetics [24] . This report suggests that aspirininsensitive mechanisms of platelet activation and thrombus formation may operate in diabetics.
Cilostazol is a different type of antiplatelet agent that inhibits type 3 phosphodiesterase in platelets and decreases thromboxane formation by enhancement of the platelet cAMP level. Interestingly, previous studies have shown that cilostazol can improve dyslipidemia in diabetics. Treatment by this agent led to a decrease of the serum TG level and an increase of the serum HDL-C level [25, 26] . In the present study, serum TG level was reduced in the cilostazol group but not significantly, probably because of the small number of subjects with not significantly high enough level of TG at baseline.
Cilostazol also showed an antiatherogenic effect on endothelial cells and vascular smooth muscle cells. Because type 3 phosphodiesterase is not only present in platelets but also in endothelial cells and smooth muscle cells, inhibition of this enzyme by cilostazol results in enhancement of NO production, increased blood flow, and attenuation of smooth muscle cell proliferation [6, 7, 27, 28] . Taken together, these findings suggest that cilostazol may have a broad preventive effect from the early to advanced stage of atherosclerosis by such multiple actions. However, the results of the present study were limited, because it was a short-term trial in a small number of subjects, and there have been no large-scale prospective studies regarding the effect of cilostazol on atherosclerosis or comparing cilostazol with aspirin. An international prospective trial (Japan, Korea, China, and the Philippines) that will evaluate the anti-atherogenic effect of cilostazol and compare it with low-dose aspirin in diabetics using carotid IMT as a marker as well as the incidence of cardiovascular events is scheduled to start soon, and this study may provide valuable information about the anti-atherosclerotic effect of cilostazol.
In conclusion, cilostazol inhibited the increase of IMT in type 2 diabetic patients. A large-scale prospective study is needed to confirm the present findings.
